Detalhe da pesquisa
1.
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.
Proc Natl Acad Sci U S A
; 110(19): 7922-7, 2013 May 07.
Artigo
Inglês
| MEDLINE | ID: mdl-23620515
2.
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Blood
; 121(13): 2533-41, 2013 Mar 28.
Artigo
Inglês
| MEDLINE | ID: mdl-23361907
3.
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Blood
; 122(6): 1017-25, 2013 Aug 08.
Artigo
Inglês
| MEDLINE | ID: mdl-23801631
4.
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Nat Chem Biol
; 8(11): 890-6, 2012 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-23023262
5.
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Biopharm Drug Dispos
; 35(4): 237-52, 2014 May.
Artigo
Inglês
| MEDLINE | ID: mdl-24415392
6.
Structural Approaches to Cancer Drug Development.
N Engl J Med
; 373(5): 402-3, 2015 Jul 30.
Artigo
Inglês
| MEDLINE | ID: mdl-26222556
7.
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.
Proc Natl Acad Sci U S A
; 107(49): 20980-5, 2010 Dec 07.
Artigo
Inglês
| MEDLINE | ID: mdl-21078963
8.
Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
J Biol Chem
; 286(8): 6433-48, 2011 Feb 25.
Artigo
Inglês
| MEDLINE | ID: mdl-21118801
9.
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.
Am J Pathol
; 177(1): 415-23, 2010 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-20489150
10.
A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants.
Cell Chem Biol
; 28(8): 1158-1168.e13, 2021 08 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33705687
11.
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.
Cancer Cell
; 39(9): 1214-1226.e10, 2021 09 13.
Artigo
Inglês
| MEDLINE | ID: mdl-34375612
12.
Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.
Int J Toxicol
; 29(1): 3-19, 2010.
Artigo
Inglês
| MEDLINE | ID: mdl-19903873
13.
Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells.
Clin Cancer Res
; 14(18): 5735-42, 2008 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18794082
14.
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.
Clin Cancer Res
; 13(24): 7237-42, 2007 Dec 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18094401
15.
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Mol Cancer Ther
; 6(1): 51-60, 2007 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-17218635
16.
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Clin Cancer Res
; 12(19): 5869-78, 2006 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-17020995
17.
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Mol Cancer Ther
; 5(8): 1967-74, 2006 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-16928817
18.
Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
PLoS One
; 12(9): e0185092, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28950000
19.
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
J Clin Oncol
; 23(17): 3923-31, 2005 Jun 10.
Artigo
Inglês
| MEDLINE | ID: mdl-15897550
20.
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Clin Cancer Res
; 11(17): 6382-9, 2005 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-16144943